medigraphic.com
Boletín Médico del Hospital Infantil de México

2013, Number 2

<< Back Next >>

Bol Med Hosp Infant Mex 2013; 70 (2)

Expression of BART-5, BART-16 and BART-22, and NF-κB factor in classic Hodgkin’s lymphoma in pediatric patients

López-Facio KL, Eguía-Aguilar P, Valencia-Mayoral P, Pérezpeña-Díazconti M, Arenas-Huertero F

Language: English
References: 29
Page: 98-106
PDF size: 398.13 Kb.


ABSTRACT

Background. Classic Hodgkin’s lymphoma (CHL) is a neoplasm in which the presence of, or infection by, the Epstein-Barr virus (EBV) is associated with disease development. Two aspects of this condition are currently unknown: first, whether molecular regulators such as the microRNAs of EBV are expressed and second, if there is an association with inflammation-promoting, neoplastic factors in pediatric CHL. The aim of the present study was to use RT-PCR to analyze the expression of the specific microRNAs of EBV called BARTs, specifically BARTs-5, -16 and -22 and that of factor NF-κB, also using RT-PCR.
Methods. A total of 24 cases were selected after meeting the inclusion criteria, which involved different varieties of CHL including the nodular sclerosis (NS) and mixed cellularity (MC) types. These resulted in being the most common ones, each with a frequency of 41.6%.
Results. BART-5 was the one most frequently expressed in CHL, at 83.3%. BART-22 was the second most frequent, at 33.3%, compared to 0% in controls (reactive lymph nodes, RLN). In all cases, the differences compared to RLN were significant (p ‹0.05). Expression of NF-κB was found in 62.5% of CHL cases and was present in 83.3% of RLN (p ‹0.05). The MC type expressed it in 90% of cases, compared to only 20% for the NS variety (p ‹0.05).
Conclusions. BART-5 was the one most frequently expressed in CHL cases. NF-κB factor is an important indicator of inflammation most often expressed in RLN.


REFERENCES

  1. Stein H, Deisol G, Pileri S, Said J, Man R, Popema S, et al. Classical Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues; 2008. Lyon: IARC. pp. 326-329.

  2. Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE. Nathan and Oski’s Haemathology of Infancy and Childhood; 2003. Philadelphia: Saunders Elsevier.

  3. Diehl V. Hodgkin’s disease—from pathology specimen to cure. N Engl J Med 2007;357:1968-1971.

  4. Departamento de Bioestadística y Archivo Clínico del Hospital Infantil de México Federico Gómez, 2010.

  5. Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma 2009;9:206-216. doi: 10.3816/CLM.2009.n.042.

  6. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009;11:1174-1184.

  7. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 1973;70:190-194.

  8. Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 2005;15:149-156.

  9. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology; 2001. Philadelphia: Lippincott-Williams and Wilkins. pp. 2511-2573.

  10. Raab-Traub N, Hood R, Yang CS, Henry B II, Pagano JS. Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol 1983;48:580-590.

  11. Young L, Alfieri C, Hennessy K, Evans H, O’Hara C, Anderson KC, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-1085.

  12. Cai X, Schäfer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006;2:e23.

  13. Hitt MM, Allday MJ, Hara T, Karran L, Jones MD, Busson P, et al. EBV gene expression in an NPC-related tumor. EMBO J 1989;8:2639-2651.

  14. Sadler RH, Raab-Traub N. Structural analyses of the Epstein-Barr virus BamHI A transcripts. J Virol 1995;69:1132-1141.

  15. Karran L, Gao Y, Smith PR, Griffin BE. Expression of a family of complementary-strand transcripts in Epstein-Barr virus-infected cells. Proc Natl Acad Sci USA 1992;89:8058-8062.

  16. Gottwein E, Cullen BR. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 2008;3:375-387. doi: 10.1016/j.chom.2008.05.002.

  17. Grivennikov SI, Greten F, Karin M. Immunity, inflammation,and cancer. Cell 2010;140:883-899.

  18. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009;27:693-733. doi: 10.1146/annurev.immunol.021908.132641.

  19. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2009;19:404-413. doi: 10.1016/j.tcb.2009.05.006.

  20. Chaturvedi M, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kB addiction and its role in cancer: ‘one size does not fit all’. Oncogene 2011;30:1615-1630. doi: 10.1038/onc.2010.566.

  21. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006;25:6831-6843.

  22. Hoffmann A, Xia Y, Verma IM. Inflammatory tales of liver cancer. Cancer Cell 2007;11:99-101.

  23. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008;205:2551-2560. doi: 10.1084/jem.20072581.

  24. Ouellet DL, Provos P. Current knowledge of microRNAs and noncoding RNAs in virus-infected cells. Methods Mol Biol 2010;623:35-65. doi: 10.1007/978-1-60761-588-0_3.

  25. Kim DN, Chae HS, Oh ST, Kang JH, Park CH, Park WS, et al. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol 2007;81:1033-1036. doi: 10.1128/JVI.02271-06.

  26. Ghosh Z, Mallick B, Chakrabarti J. Cellular versus viral microRNAs in host–virus interaction. Nucleic Acids Res 2009;37:1035-1048. doi: 10.1093/nar/gkn1004.

  27. Cullen BR. Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev 2011;25:1881-1894. doi: 10.1101/gad.17352611.

  28. Moens U. Silencing viral microRNA as a novel antiviral therapy? J Biomed Biotech 2009. doi: 10.1155/2009/419539.

  29. Edwards RH, Marquitz AR, Raab-Traub N. Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 2008;82:9094-9106.




2020     |     www.medigraphic.com